Literature DB >> 32356006

First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using 68Ga-PSMA-11.

Christopher Darr1, U Krafft2, W P Fendler3, P Fragoso Costa3, F Barbato3, C Praus3, H Reis4, T Hager4, S Tschirdewahn2, J P Radtke2, K Herrmann3, B A Hadaschik2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32356006     DOI： 10.1007/s00259-020-04778-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  4 in total

1.  Sensitivity improved Cerenkov luminescence endoscopy using optimal system parameters.

Authors:  Xueli Chen; Xinyu Wang; Xiangfeng Meng; Tianyu Yan; Yun Zheng; Honghao Cao; Feng Ren; Xu Cao; Xiaojian Lu; Shuhui Liang; Kaichun Wu
Journal:  Quant Imaging Med Surg       Date:  2022-01

2.  Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging-utilization of a short-pass filter to reduce technical pitfalls.

Authors:  Boris Alexander Hadaschik; Stephan Tschirdewahn; Christopher Darr; Pedro Fragoso Costa; Claudia Kesch; Ulrich Krafft; Lukas Püllen; Nina Natascha Harke; Jochen Hess; Tibor Szarvas; Johannes Haubold; Henning Reis; Wolfgang Peter Fendler; Ken Herrmann; Jan Philipp Radtke
Journal:  Transl Androl Urol       Date:  2021-10

3.  Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location.

Authors:  Magdalena Skubal; Benedict Mc Larney; Pamela Causa-Andrieu; Edwin C Pratt; Sudeep Das; Peter Sawan; Abdallah Araji; Christopher Riedl; Kunal Vyas; David Tuch; Jan Grimm
Journal:  Nat Biomed Eng       Date:  2022-04-11       Impact factor: 29.234

Review 4.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.